The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

Delhi has long stood as a beacon of modern healthcare. The national capital is home to gleaming hospitals, internationally ...

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has ...